PubMed:18783504 JSONTXT 2 Projects

Psychological mediators of bupropion sustained-release treatment for smoking cessation. AIM: The study aimed to test simultaneously our understanding of the effects of bupropion sustained-release (SR) treatment on putative mediators and our understanding of determinants of post-quit abstinence, including withdrawal distress, cigarette craving, positive affect and subjective reactions to cigarettes smoked during a lapse. The specificity of bupropion SR effects was also tested in exploratory analyses. DESIGN: Data from a randomized, placebo-controlled clinical trial of bupropion SR were submitted to mediation analyses. SETTING: Center for Tobacco Research and Intervention, Madison, WI, USA. PARTICIPANTS: A total of 403 adult, daily smokers without contraindications to bupropion SR use. INTERVENTION: Participants were assigned randomly to receive a 9-week course of bupropion SR or placebo pill and to receive eight brief individual counseling sessions or no counseling. MEASUREMENTS: Ecological momentary assessment ratings of smoking behavior and putative mediators were collected pre- and post-quit. FINDINGS: Results of structural equation and hierarchical linear models did not support the hypothesis that bupropion SR treatment improves short-term abstinence by reducing withdrawal distress or affecting the subjective effects of a lapse cigarette, but provided partial support for mediation by cigarette craving reduction and enhanced positive affect. Bupropion SR effects on point-prevalence abstinence at 1 month post-quit were also mediated partially by enhanced motivation to quit and self-efficacy. CONCLUSIONS: Results provided some support for models of bupropion SR treatment and relapse and suggested that motivational processes may partially account for bupropion SR efficacy.